The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?

Comparator sourcing: Leveraging the Bolar exemption to accelerate market access for generic and biosimilar products

Whitepaper

This whitepaper provides insight into the changing comparator sourcing landscape, focusing specifically on the instrumental role the Bolar exemption plays in the shift away from dependence on innovators for clinical supplies. Thermo Fisher's Comparator team has the required expertise to leverage the Bolar exemption, providing clients early access to generic / biosimilar drugs.